BHCM
XENE icon

Brevan Howard Capital Management’s Xenon Pharmaceuticals XENE Stock Holding History

Brevan Howard Capital Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$700K Buy
+12,041
New +$555K 0.01% 1105
2025
Q1 		– Sell
-19,005
Closed -$745K – 1510
2024
Q4 		$745K Buy
19,005
+6,993
+58% +$289K ﹤0.01% 509
2024
Q3 		$473K Buy
+12,012
New +$484K ﹤0.01% 696

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Brevan Howard Capital Management's XENE Position: Q1 2026 in Review

Brevan Howard Capital Management opened a new position in Xenon Pharmaceuticals (XENE) in Q1 2026: 12,041 shares worth $700K. The stake represents 0.01% of the portfolio and ranks #1105 among its holdings. This is a return to the name: Brevan Howard Capital Management previously reported a position in XENE as recently as Q4 2024.

Brevan Howard Capital Management first reported a position in XENE in Q3 2024 and has held it in 3 quarters since. The position peaked at $745K in Q4 2024. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

  • Brevan Howard Capital Management held 12,041 shares of Xenon Pharmaceuticals worth $700K as of Q1 2026.
  • Xenon Pharmaceuticals was a new Brevan Howard Capital Management position in Q1 2026.
  • Xenon Pharmaceuticals made up 0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #1105 holding.
  • Brevan Howard Capital Management first reported a position in Xenon Pharmaceuticals in Q3 2024 and has held it in 3 quarters since.
  • Brevan Howard Capital Management's Xenon Pharmaceuticals position peaked at $745K in Q4 2024.
  • 290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.